BioXcel Therapeutics, Inc. is a biopharmaceutical company leveraging artificial intelligence to develop medicines in neuroscience and immuno-oncology through its subsidiary, OnkosXcel Therapeutics. Co.'s neuroscience candidate, BXCL501, is an investigational, orally dissolving film for treating agitation in psychiatric and neurological disorders, including bipolar disorders, schizophrenia and Alzheimer's-related dementia, for both at-home and care facility settings. Co.'s immuno-oncology candidate, BXCL701, is an oral innate immune activator aimed at treating aggressive prostate cancer, pancreatic cancer and other solid and liquid tumors. The BTAI YTD return is shown above.
The YTD Return on the BTAI YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether BTAI YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BTAI YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|